Form 4: Apellis Pharmaceuticals Director Exercises Stock Options and Reports Beneficial Ownership
SEC Form 4 Filing
Director A. Sinclair Dunlop exercised stock options and reported changes in beneficial ownership of Apellis Pharmaceuticals, Inc. shares.
Summary
- On April 12, 2024, A. Sinclair Dunlop, a director of Apellis Pharmaceuticals, Inc., exercised stock options to acquire 1,500 shares of common stock at a price of $13.19 per share.
- Following the transaction, Dunlop directly owns 133,518 shares of Apellis common stock.
- Dunlop also indirectly owns 173,998 shares through Epidarex and 31,855 shares through MASA.
- The exercised stock options were granted on January 1, 2019, and were fully vested.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity.
Positives
- The exercise of stock options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.
Stakeholder Impact
- The transaction may have a minor impact on shareholders as it involves the issuance of new shares.
Key Dates
| Date | Description |
|---|---|
| January 1, 2019 | Date the stock options were granted and fully vested. |
| April 12, 2024 | Date of the stock option exercise. |
| April 15, 2024 | Date of the signature on the Form 4 filing. |
| December 31, 2028 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.